Browse All

Current Filters

CLEAR FILTER x

TITLE

Clinical Relevance of Donanemab Treatment

Author:Atri, Alireza   Wessels, Alette   Doty, Erin   Atkins, Alexandra   Chandler, Julie   Lu, Ming   Ye, Wenyu   Dennehy, Ellen   Brooks, Dawn   Sims, John   

Session Name:S1: Alzheimer’s Disease and Related Dementias  

Topic:Aging, Dementia, Cognitive, and Behavioral Neurology  

Program Number:S1.004  

Author Institution:Banner Sun Health Research Institute, Sun City, AZ  Eli Lilly and Company, Indianapolis, IN  Eli Lilly, Indianapolis, IN  

ARIA Insights from the Donanemab Trials

Author:Greenberg, Steven   Battioui, Chakib   Lu, Ming   Biffi, Alessandro   Ardayfio, Paul   Zimmer, Jennifer   Evans, Cynthia   Wang, Hong   Monkul Nery, Emel Serap   Sparks, JonDavid   Andersen, Scott   Collins, Emily   Brooks, Dawn   Sims, John   

Session Name:P1: Aging, Dementia, Cognitive, and Behavioral Neurology: Diagnostic Imaging  

Topic:Aging, Dementia, Cognitive, and Behavioral Neurology  

Program Number:P1.001  

Author Institution:Massachusetts General Hospital, Boston, MA  Eli Lilly and Company, Indianapolis, IN  

Understanding Patients’ Journeys Prior to Initiating Calcitonin Gene-related Peptide Monoclonal Antibody for Migraine Prevention in the United States

Author:Vincent, Maurice   Hoyt, Margaret   Lenderking, William R.   Hetherington, Lucinda   Ruff, Dustin   Kim, Gilwan   Viktrup, Lars   

Session Name:P8: Headache: Advances in CGRP Inhibition 2  

Topic:Headache  

Program Number:P8.008  

Author Institution:Eli Lilly and Company, Indianapolis, IN  Evidera, Bethesda, MD  Evidera, London, United Kingdom  

Interictal Burden Before Initiating Calcitonin Gene-related Peptide Monoclonal Antibody for Migraine Prevention

Author:Vincent, Maurice   Hoyt, Margaret   Lenderking, William R.   Hetherington, Lucinda   Ruff, Dustin   Kim, Gilwan   Viktrup, Lars   

Session Name:P9: Headache: Advances in CGRP Inhibition 3  

Topic:Headache  

Program Number:P9.003  

Author Institution:Eli Lilly and Company, Indianapolis, IN  Evidera, Bethesda, MD  Evidera, London, United Kingdom  

Microglial-targeted Gene Therapy: Developing a Disease Modifying Treatment for ALSP Associated with CSF1R Mutations (ALSP-CSF1R)

Author:Masoudi, Neda   Willen, Jessie   Daniels, Carter   Jenkins, Beverly Ann   Conceicao Furber, Ellen   Kothiya, Milankumar   Banjoko, Michael B.   Gowda, Raghu   Hendricks, Jeremiah   Fang, Yi-Ya   Raut, Priyam   Arnaout, Adnan   Bassil, Fares   Wong, LiChin   Daniels, Garrett   Haller, Jorge Francisco   Kamalakaran, Sid   Lewis, Travis   Day, Theresa Ann   Shykind, Benjamin   Shannon, Mansuo   Hefti, Franz   Sen, Anindya   

Session Name:P11: General Neurology: Novel Concepts  

Topic:General Neurology  

Program Number:P11.012  

Author Institution:Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY  Eli Lilly and Company, New York, NY  Eli Lilly and Company, Indianapolis, IN